BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:59 PM
 | 
Oct 25, 2012
 |  BC Extra  |  Company News

Novartis seeks approval of QVA149 in Europe

Novartis AG (NYSE:NVS; SIX:NOVN) submitted a regulatory application to EMA for QVA149 to treat chronic obstructive pulmonary disease (COPD). QVA149 is a fixed-dose combination of NVA237, an inhaled long-acting...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >